Jacob Sands, MD, is associate chief of the Lowe Center for Thoracic Oncology and oncology medical director of the International Patient Center at Dana-Farber Cancer Institute; as well as an assistant professor at Harvard Medical School
Panelists agreed the ADRIATIC trial is practice-changing for limited-stage small cell lung cancer, establishing durvalumab as the new standard post chemoradiation due to its significant survival benefit and manageable toxicity, while also highlighting the need for multidisciplinary coordination and raising questions about agent selection and evolving radiation strategies.
Jacob Sands, MD, presents promising early-phase trial results for obrixtamig, a novel DLL3-targeting T-cell engager, in patients with large cell neuroendocrine carcinoma of the lung (LCNEC-L), shared at ESMO Congress 2024.
Panelists discuss the unmet needs and future perspectives in the treatment of RET-positive non–small cell lung cancer (NSCLC), focusing on areas for improvement in therapy and the potential for new treatment strategies.
Panelists discuss how to monitor patients for response to treatment and early signs of resistance in RET fusion–positive non–small cell lung cancer (NSCLC), including the approach to follow-up molecular testing, and describe strategies for treatment sequencing after disease progression on RET inhibitors.
Panelists discuss the common adverse effects for patients receiving selpercatinib or pralsetinib, strategies for managing these effects, and whether differences in the safety profiles of these drugs influence treatment choices for RET fusion–positive non–small cell lung cancer.
Panelists discuss the situations in which other first-line therapies, such as cabozantinib or PD-L1–positive chemotherapy options, might be considered for RET fusion–positive non–small cell lung cancer (NSCLC), and compare the role of chemotherapy and immunotherapy to that of RET inhibitors in this setting.
Panelists discuss the specific factors that influence the decision to initiate one of the NCCN guideline–preferred RET inhibitors, selpercatinib or pralsetinib, over the other in the treatment of RET fusion–positive NSCLC.
Panelists discuss their initial impressions of a patient case with RET fusion–positive non–small cell lung cancer (NSCLC), treatment goals for newly diagnosed patients, and the key patient and disease characteristics considered when selecting a first-line treatment regimen.
Panelists discuss the initial approach to the management of RET-positive non–small cell lung cancer (NSCLC), focusing on treatment strategies and the role of targeted therapies such as RET inhibitors in first-line treatment.
Panelists discuss how to balance the need for comprehensive biomarker testing with the urgency to initiate treatment in patients with advanced disease and explore situations where treatment might be started before test results are available.
Panelists discuss strategies for clinicians without access to in-house molecular testing, focusing on how to ensure appropriate turnaround times when outsourcing tests and share insights on the typical timeline for receiving biomarker testing results at their respective institutions.
Panelists discuss the various tests available for detecting genetic mutations in advanced non–small cell lung cancer (NSCLC), including next-generation sequencing (NGS), reverse transcription polymerase chain reaction (RT-PCR), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and Sanger sequencing, and explore whether one method is considered the “gold standard” according to the NCCN guidelines. They also address the appropriate use of circulating tumor DNA (ctDNA) testing, comparing it to tissue testing in this disease state.
Panelists discuss how molecular testing is crucial in guiding treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the prevalence of mutations like BRAF, KRAS, MET, RET, and EGFR, and their impact on selecting targeted therapies.
Panelists discuss how the treatment approach for a 67-year-old man with stage IIIB+ non–small cell lung cancer (NSCLC) awaiting mutation testing involves balancing the urgency of initiating therapy with the importance of molecular testing to guide targeted treatment decisions.
Jacob Sands, MD, discusses updated efficacy findings with tarlatamab treatment in previously treated patients with small cell lung cancer.
Jacob Sands, MD, discusses consolidation therapy durvalumab as a new standard of care in limited-stage small cell lung cancer.
Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.
Jacob Sands, MD, shares updated data from the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan versus docetaxel in non-squamous non-small cell lung cancer recently presented at the 2024 European Lung Cancer Congress (ELCC).
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
In this expert interview, Jacob Sands, MD, shares key insights on unmet needs in the treatment of lung cancer, comments on the role of clinical trials investigating Trop-2-targeted therapy, and considers the potential impact of datopotamab deruxtecan (Dato-DXd) on the treatment landscape if it receives FDA approval for use in lung cancer.
Jacob Sands, MD, physician, discusses the importance of next-generation sequencing testing in lung cancer.
Jacob Sands, MD, discusses the FDA approval of lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer with disease progression, following platinum-based chemotherapy.
Jacob Sands, MD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, discusses the rationale to explore DS-1062 in advanced non–small cell lung cancer (NSCLC).
